Ultomiris is a medication used for the treatment of generalized myasthenia gravis
(gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive as well as those with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Ultomiris is given as an IV infusion every 8 weeks after 2 initial doses.
Potential Side Effects
SERIOUS MENINGOCOCCAL INFECTIONS: Immunize patients with
meningococcal vaccines at least 2 weeks prior to administering the first dose
Meningococcal vaccination (both conjugate and serogroup B) are required
prior to initiating Ultomiris infusions.
Before you attend your first appointment at Sage Infusion, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!
Find a Sage Infusion Location Near You
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
SEARCH BY ZIP